SOUTH SAN FRANCISCO, Calif., September 23, 2021 – GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has closed a $26 million Series A financing. New investors Eli Lilly, KTB Network, Ltd., Company K Partners, Korea Investment Partners, DAYLI Partners, […] The post GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021 first appeared on BreezeBio .